REPLICEL LIFE SCIENCES INC. | CIK:0001205059 | 3

  • Filed: 5/11/2018
  • Entity registrant name: REPLICEL LIFE SCIENCES INC. (CIK: 0001205059)
  • Generator: Compliance Xpressware
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1205059/000106299318002112/0001062993-18-002112-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1205059/000106299318002112/repcf-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001205059
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory

      f)

    Basic and Diluted Loss per Share

         
       

    Basic loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the relevant period.

         
       

    Diluted earnings/loss per common share is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted.

         
       

    The number of shares potentially issuable at December 31, 2017 that were not included in the computation of loss per share totaled 14,148,898 (2016: 12,310,910 ; 2015: 2,349,785) consisting of 1,400,000 (2016:1,417,000; 2015: 484,000) outstanding stock options; nil (2016: nil; 2015: 170,000) contingently issuable common shares held in escrow to be released upon the occurrence of certain milestones (Note 8(f)); 12,748,898 (2016: 10,848,439 ; 2015: 1,650,314) warrants; and nil (2016: 45,471 ; 2015: 45,471) agents’ options (Note 8(i)).